Establishment and characterization of a new human gallbladder cancer cell line, OCUG-2

Figure 3 Expression of growth factor receptors and growth kinetics. A: mRNA expression of growth factor receptors EGFR, HER2, ERBB3, ERBB4, PDGFR-α, PDGFR-β, insulin-like growth factor 1 receptor, FMS-like tyrosine kinase, FGFR1, FGFR2, FGFR3, FGFR4, VEGFR1, VEGFR2, VEGFR3, c-Kit, and c-Met; B: Growth curves of OCUG-2 cells treated with panitumumab, cetuximab, bevacizumab, ramucirumab, CP673451, picropodophyllin, SU11274, infigratinib, FGF401, afatinib, sapitinib, and trastuzumab. Growth of OCUG-2 cells was significantly decreased by picropodophyllotoxin.